Silicon Valley Billionaires Invest Billions in Anti-Aging Technologies

Immortality remains the stuff of science fiction, but Silicon Valley billionaires are willing to spend enormous sums on research that could slow aging and return cells to a younger state. One of the most promising fields is cellular reprogramming, a technology based on delivering specific instructions to cells to alter their state and partially reverse age-related changes.

Among the investors interested in this field are Amazon founder Jeff Bezos and OpenAI CEO Sam Altman. Biotechnology companies are exploring ways to restore the function of aging cells, with the long-term goal of treating age-related diseases and extending healthy lifespans. Research is already advancing into early-stage clinical trials. According to a Yahoo report, the first procedures using these technologies have been performed on three patients. No serious side effects have reportedly been identified so far, and two participants experienced improvements in their vision. However, such a small number of patients is insufficient to draw definitive conclusions about the treatment’s effectiveness and safety. Larger studies and long-term monitoring will be needed to confirm the results.

While scientists work to understand the mechanisms of aging and find ways to influence them, some Silicon Valley entrepreneurs are experimenting with their own longevity programs. Bryan Johnson, known for his expensive procedures and rigorous monitoring of his body’s health markers, says he spends around $2 million a year on maintaining his health and attempting to slow aging. As part of his experiments, he has also used blood plasma from his son, although there is no compelling scientific evidence that such procedures extend human life.

Sam Altman, meanwhile, has spoken about following a fasting routine lasting approximately 15 hours and using a special lamp in the morning. Peter Thiel, PayPal co-founder and investor, is also interested in life-extension technologies and has reportedly used growth hormone in the hope of living to 120. However, growth hormone has not been proven to extend the lives of healthy people, and its use can involve serious side effects.

Despite rapidly growing investment in biotechnology, significantly extending human life remains a long-term challenge. Scientists still need to demonstrate that cellular reprogramming can genuinely restore tissue function without increasing the risk of cancer or other dangerous complications. They must also determine whether these methods can be safely applied throughout the entire body.

Today, the main goal of this research is not literal immortality but extending the period of life during which people remain healthy and active. Nevertheless, the interest of major investors shows that the fight against aging is gradually evolving from a niche scientific topic into a promising area of the biotechnology industry. If new methods prove effective, they could transform approaches to treating age-related diseases and have a substantial impact on the future of medicine.

The first cellular reprogramming therapy aims to rejuvenate eye tissue and restore vision.

Photo: Edward Berthelot/Getty Images